ACTG A5264 (Treatment of early KS) ACTG A5288 (MULTI-OCTAVE [3rd-line ART in RLS]) ACTG A5290 (Rifabutin and LPV/r) ACTG A5297 (PIs and malaria) ACTG A5300 (PHOENIx feasibility study) ACTG A5307 (Essentiality of INH) ACTG A5316 (PK of ART and vaginal ring contraceptive) ACTG A5317 (Methotrexate) ACTG A5325 (Isotretinoin) ACTG A5340 (ATI after VRC01) ACTG A5342 (VRC01 and the reservoir)
Progress on ACTG Trials
9 studies completed follow-up – – – – – – – – –
ACTG A5274 (REMEMBER) ACTG A5297 (PIs and malaria) ACTG A5298 (HPV vaccine) ACTG A5305 (HPTN 069; MVC for PrEP) ACTG A5307 (Essentiality of INH) ACTG A5314 (Telmisartan) ACTG A5317 (Methotrexate) ACTG A5326 (anti-PD-L1 Ab) ACTG A5340 (ATI after VRC01)
ACTG Accrual (June, 2015– May, 2016) 2116 enrolled into interventional trials 1326 enrolled into A5300 (over 6 months!) 445 enrolled into other observational studies 926 enrolled into A5128 or A5243 4813 participants enrolled across all studies 2544 participants enrolled at international sites 2108 participants enrolled at US sites 161 participants enrolled at non-ACTG CRSs
ACTG Abstracts and Publications
51 abstracts presented at 11 meetings 61 manuscripts published or in press – – – – – – – –
AIDS Res Hum Retrovir 3 AIDS 9 Ann Intern Med 2 Clin Infect Dis 10 JAIDS 8 J Infect Dis 6 Lancet 1 Nat Med 1